You have free access to this content

Cancer

Cover image for Cancer

1 June 1999

Volume 85, Issue 11

Pages 2301–2495

  1. Editorial

    1. Top of page
    2. Editorial
    3. Original Articles
    4. Correspondence
    1. You have free access to this content
      Pregnancy after breast carcinoma : The ultimate medical challenge (pages 2301–2304)

      Hervy E. Averette, Ramin Mirhashemi and Frederick L. Moffat

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2301::AID-CNCR1>3.0.CO;2-A

      Premenopausal breast carcinoma survivors frequently have questions and concerns regarding future childbearing. The results of the study by Velentgas et al. show that the prognosis of patients with breast carcinoma does not appear to be altered by subsequent pregnancy.

      See also pages 2424–32.

  2. Original Articles

    1. Top of page
    2. Editorial
    3. Original Articles
    4. Correspondence
    1. You have free access to this content
      Extramedullary plasmacytoma : Tumor occurrence and therapeutic concepts (pages 2305–2314)

      Christoph Alexiou, Reinhardt J. Kau, Hermann Dietzfelbinger, Marcus Kremer, Jens C. Spieß, Bruno Schratzenstaller and Wolfgang Arnold

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2305::AID-CNCR2>3.0.CO;2-3

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      Extramedullary plasmacytoma (EMP) is related to non-Hodgkin lymphoma and occurs mainly in the upper aerodigestive tract. General therapeutic concepts are lacking. This is the first evaluation of all EMP cases published in the medical literature, including a presentation of the authors' own seven cases. The aim of this evaluation was to provide a detailed analysis of the distribution and treatment of this tumor.

    2. Anatomic Site

      You have free access to this content
      Clinicopathologic significance of laminin-5 γ2 chain expression in squamous cell carcinoma of the tongue : Immunohistochemical analysis of 67 lesions (pages 2315–2321)

      Yukiko Ono, Yukihiro Nakanishi, Yoshinori Ino, Toshiro Niki, Tesshi Yamada, Kimio Yoshimura, Masahisa Saikawa, Tamio Nakajima and Setsuo Hirohashi

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2315::AID-CNCR3>3.0.CO;2-Y

      • original image
      • original image
      • original image

      Increased cytoplasmic laminin-5 γ2 chain immunoreactivity, which may reflect a high potential of cancer cell invasiveness, is a factor indicative of a poor prognosis for patients with squamous cell carcinoma of the tongue.

    3. You have free access to this content
      Flow cytometric DNA analysis is useful in detecting multiple genetic alterations in squamous cell carcinoma of the esophagus (pages 2322–2328)

      Masayuki Watanabe, Hiroyuki Kuwano, Shinji Tanaka, Yasushi Toh, Noriaki Sadanaga and Keizo Sugimachi

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2322::AID-CNCR4>3.0.CO;2-V

      • original image
      • original image

      Flow cytometric DNA analysis is useful in detecting multiple genetic alterations as well as in predicting the prognosis of patients with carcinoma of the esophagus.

    4. You have free access to this content
      Clinical significance of spontaneous apoptosis in advanced gastric adenocarcinoma (pages 2329–2335)

      Masahide Ikeguchi, Jianhui Cai, Nariyuki Yamane, Michio Maeta and Nobuaki Kaibara

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2329::AID-CNCR5>3.0.CO;2-L

      • original image
      • original image
      • original image

      Less extensive apoptosis in gastric carcinoma may contribute to disease progression and may be correlated with a poorer prognosis.

    5. You have free access to this content
      Combination chemotherapy with granulocyte-macrophage–colony stimulating factor in patients with locoregional and metastatic gastric adenocarcinoma (pages 2336–2339)

      Susan Partyka, Pamela Dumas and Jaffer Ajani

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2336::AID-CNCR6>3.0.CO;2-I

      Granulocyte-macrophage–colony stimulating factor effectively attenuated granulocytopenia caused by the combination of 5-fluorouracil, folinic acid, and etoposide given to 30 patients with advanced gastric adenocarcinoma. However, this combination chemotherapy is not recommended because of a low response rate (14%).

    6. You have free access to this content
      Intratumoral neovascularization and growth pattern in early gastric carcinoma (pages 2340–2346)

      Masaaki Tomoda, Yoshihiko Maehara, Yoshihiro Kakeji, Shinji Ohno, Yuji Ichiyoshi and Keizo Sugimachi

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2340::AID-CNCR7>3.0.CO;2-I

      • original image
      • original image
      • original image
      • original image
      • original image

      Early gastric carcinoma of expansively penetrating growth type tends to secrete vascular endothelial growth factor, thus inducing tumor angiogenesis and resulting in venous invasion, hematogenous metastases, and recurrence.

    7. You have free access to this content
      Combined paclitaxel, cisplatin, and etoposide for patients with previously untreated esophageal and gastroesophageal carcinomas (pages 2347–2351)

      Jacob J. Lokich, Henry Sonneborn, Norwood R. Anderson, Murray M. Bern, Frank V. Coco, Edward Dow and Peter Oliynyk

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2347::AID-CNCR8>3.0.CO;2-8

      Paclitaxel, cisplatin, and etoposide administered twice weekly on a unique schedule yielded a high response rate among patients with tumors of the esophagus, gastroesophageal junction, and stomach. Responses were lasting and resulted in the downstaging of a significant proportion of tumors.

    8. You have free access to this content
      Malignant fibrous histiocytoma of the pancreas : A case report with genetic analysis (pages 2352–2358)

      Daniel Bastian, Annette Ramaswamy, Peter J. Barth, Berthold Gerdes, Michael Ernst and Detlef Bartsch

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2352::AID-CNCR9>3.0.CO;2-7

      • original image
      • original image
      • original image
      • original image
      • original image

      To the authors' knowledge, this is the first genetic and immunohistochemical analysis of the p16, p53, and DPC4 tumor suppressor genes as well as the K-ras oncogene in malignant fibrous histiocytoma of the pancreas.

    9. You have free access to this content
      Lung carcinoma : Analysis of T helper type 1 and 2 cells and T cytotoxic type 1 and 2 cells by intracellular cytokine detection with flow cytometry (pages 2359–2367)

      Norimasa Ito, Hiroshige Nakamura, Yoshiyuki Tanaka and Shigetsugu Ohgi

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2359::AID-CNCR10>3.0.CO;2-A

      • original image
      • original image
      • original image
      • original image
      • original image

      A favorable pathway in which T helper type 1 cells (Th1) and T cytotoxic type 1 cells (Tc1) are dominant is induced in the tumor tissues of operable patients, but that pathway can be expected to shift from Th1 or Tc1 to Th2 or Tc2 with the progression of cancer.

    10. You have free access to this content
      Pleuropulmonary blastoma in an adult : An initial case report (pages 2368–2374)

      D. Ashley Hill, Saeed Sadeghi, Michelle Z. Schultz, John S. Burr and Louis P. Dehner

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2368::AID-CNCR11>3.0.CO;2-9

      • original image
      • original image
      • original image
      • original image
      • original image

      Pleuropulmonary blastoma (PPB) is a unique intrathoracic dysontogenetic neoplasm that to date has been observed only in children. The authors present the clinicopathologic features of a PPB that occurred in a man age 36 years, and to their knowledge this is the first report of a case in an adult.

    11. You have free access to this content
      Cisplatin in combination with irinotecan in the treatment of patients with malignant pleural mesothelioma : A pilot phase II clinical trial and pharmacokinetic profile (pages 2375–2384)

      Takashi Nakano, A. Philippe Chahinian, Miho Shinjo, Naoki Togawa, Atsushi Tonomura, Mitsutomi Miyake, Koji Ninomiya, Tetsuya Yamamoto and Kazuya Higashino

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2375::AID-CNCR12>3.0.CO;2-E

      • original image
      • original image
      • original image

      The combination of cisplatin and irinotecan (CPT-11) has been reported to have activity against malignant pleural mesothelioma. Intravenous administration of CPT-11 produces adequate distribution of CPT-11 and its active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) into the pleural fluid and allows a higher concentration of the more active SN-38 to make contact with mesothelioma cells in the thoracic cavity.

    12. You have free access to this content
      Multiple myeloma and family history of cancer among blacks and whites in the U.S. (pages 2385–2390)

      Linda Morris Brown, Martha S. Linet, Raymond S. Greenberg, Debra T. Silverman, Richard B. Hayes, G. Marie Swanson, Ann G. Schwartz, Janet B. Schoenberg, Linda M. Pottern and Joseph F. Fraumeni Jr.

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2385::AID-CNCR13>3.0.CO;2-A

      Risks of multiple myeloma were significantly elevated for subjects who reported that a first-degree relative had multiple myeloma (odds ratio = 3.7) or any hematolymphoproliferative cancer (odds ratio = 1.7) in a population-based study of 565 multiple myeloma cases and 2104 controls. Although the findings were consistent with a familial risk of multiple myeloma, they explained little of the race-related difference in incidence rates.

    13. You have free access to this content
      Can immunohistochemical markers and mitotic rate improve prognostic precision in patients with primary melanoma? (pages 2391–2399)

      Hermann Ostmeier, Blandine Fuchs, Friedrich Otto, Reinhard Mawick, Andrea Lippold, Volker Krieg and Ludwig Suter

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2391::AID-CNCR14>3.0.CO;2-I

      • original image

      Nine immunohistochemical markers with established prognostic significance for primary human melanomas were found not to improve a prognostic model that included tumor thickness, localization, and mitoses. If the mitoses category was replaced by ulceration, then the model performed slightly better, although ulceration was not significant in the presence of mitoses.

    14. You have free access to this content
      Adolescence and breast carcinoma risk (pages 2400–2409)

      Catherine S. Berkey, A. Lindsay Frazier, Jane D. Gardner and Graham A. Colditz

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2400::AID-CNCR15>3.0.CO;2-O

      • original image

      Risk of breast carcinoma was associated with earlier menarche, leaner body mass during adolescence, and taller adult height. These risk factors were consistent with an increased risk of breast carcinoma for those who experienced more rapid physical growth during adolescence.

    15. You have free access to this content
      Monitoring the response of patients with locally advanced breast carcinoma to neoadjuvant chemotherapy using [technetium 99m]-sestamibi scintimammography (pages 2410–2423)

      David A. Mankoff, Lisa K. Dunnwald, Julie R. Gralow, Georgiana K. Ellis, Mariann J. Drucker and Robert B. Livingston

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2410::AID-CNCR16>3.0.CO;2-K

      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image
      • original image

      [Technetium 99m]-sestamibi, which has been shown to have increased uptake in breast carcinoma, can measure the response of breast carcinoma patients to neoadjuvant chemotherapy.

    16. You have free access to this content
      Pregnancy after breast carcinoma : Outcomes and influence on mortality (pages 2424–2432)

      Priscilla Velentgas, Janet R. Daling, Kathleen E. Malone, Noel S. Weiss, Michelle A. Williams, Steven G. Self and Beth A. Mueller

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2424::AID-CNCR17>3.0.CO;2-4

      This follow-up study of 53 women who became pregnant after being diagnosed with breast carcinoma and a comparison group of similar breast carcinoma patients who did not become pregnant found no increase in mortality associated with pregnancy after breast carcinoma. The observed rate of miscarriages among women who became pregnant after a diagnosis of breast carcinoma was higher than expected.

      See also pages 2301–4.

    17. You have free access to this content
      Intraoperative examination of axillary sentinel lymph nodes in breast carcinoma patients (pages 2433–2438)

      Giuseppe Viale, Silvano Bosari, Giovanni Mazzarol, Viviana Galimberti, Alberto Luini, Paolo Veronesi, Giovanni Paganelli, Marilia Bedoni and Enrico Orvieto

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2433::AID-CNCR18>3.0.CO;2-3

      • original image
      • original image
      • original image

      The intraoperative examination of axillary sentinel lymph nodes can predict the axillary lymph node status of breast carcinoma patients and be instrumental in deciding whether or not to do a more extensive axillary lymph node dissection.

    18. You have free access to this content
      Lymph node metastasis from ductal carcinoma in situ with microinvasion (pages 2439–2443)

      Jeffry Zavotsky, Nora Hansen, Meghan B. Brennan, Roderick R. Turner and Armando E. Giuliano

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2439::AID-CNCR19>3.0.CO;2-J

      Sentinel lymphadenectomy is applicable to ductal carcinoma in situ with microinvasion and may add to the understanding of tumor spread in the earliest stage of invasive disease.

    19. You have free access to this content
      Does a family history of cancer increase the risk for postmenopausal endometrial carcinoma? : A prospective cohort study and a nested case–control family study of older women (pages 2444–2449)

      Janet E. Olson, Thomas A. Sellers, Kristin E. Anderson and Aaron R. Folsom

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2444::AID-CNCR20>3.0.CO;2-M

      In a large cohort study of postmenopausal women, subjects who reported a positive family history of cancer were not at increased risk for endometrial carcinoma. No evidence was found that genetics contributed to the risk of postmenopausal endometrial carcinoma among women with no previous personal history of cancer.

    20. You have free access to this content
      Is nuclear expression of Y box-binding protein-1 a new prognostic factor in ovarian serous adenocarcinoma? (pages 2450–2454)

      Toshiharu Kamura, Hideaki Yahata, Satoshi Amada, Shinji Ogawa, Takanori Sonoda, Hiroaki Kobayashi, Masamune Mitsumoto, Kimitoshi Kohno, Michihiko Kuwano and Hitoo Nakano

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2450::AID-CNCR21>3.0.CO;2-U

      • original image
      • original image
      • original image

      In the current study, the expression of Y box-binding protein-1 was found to correlate with poor prognosis in patients with ovarian serous adenocarcinoma.

    21. You have free access to this content
      p53 Alteration in regional lymph node metastases from prostate carcinoma : A marker for progression? (pages 2455–2459)

      Liang Cheng, Bradley C. Leibovich, Erik J. Bergstralh, Beth G. Scherer, Anna Pacelli, Dharamdas M. Ramnani, Horst Zincke and David G. Bostwick

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2455::AID-CNCR22>3.0.CO;2-C

      • original image
      • original image
      • original image
      • original image

      The assessment of p53 alterations in regional lymph node metastases may provide prognostic information regarding the biologic aggressiveness of regional lymph node positive prostate carcinoma, whereas p53 expression in the primary carcinoma does not appear to influence patient outcome.

    22. You have free access to this content
      Long term tolerance of high dose three-dimensional conformal radiotherapy in patients with localized prostate carcinoma (pages 2460–2468)

      Michael J. Zelefsky, Didier Cowen, Zvi Fuks, Moshe Shike, Chandra Burman, Andrew Jackson, E. S. Venkatramen and Steven A. Leibel

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2460::AID-CNCR23>3.0.CO;2-N

      • original image
      • original image
      • original image
      • original image
      • original image

      The incidence of late toxicity in 743 patients with localized prostate carcinoma treated with three-dimensional conformal radiotherapy (3D-CRT) was minimal. Radiation doses ≥75.6 gray and the presence of acute treatment-related symptoms during 3D-CRT correlated with a higher incidence of Grade ≥2 late gastrointestinal and urinary toxicities.

    23. You have free access to this content
      Survival of patients with carcinoma in situ of the urinary bladder (pages 2469–2474)

      Liang Cheng, John C. Cheville, Roxann M. Neumann, Bradley C. Leibovich, Kathleen S. Egan, Bruce E. Spotts and David G. Bostwick

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2469::AID-CNCR24>3.0.CO;2-U

      • original image
      • original image

      Patients with carcinoma in situ of the bladder are at significant risk of cancer progression and death from bladder carcinoma. In the current study cystectomy did not appear to offer a significant survival advantage for patients with carcinoma in situ of the bladder after adjusting for age.

    24. You have free access to this content
      Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms (pages 2475–2484)

      Hidenori Inohara, Yuichiro Honjo, Tadashi Yoshii, Shiro Akahani, Jun-ichi Yoshida, Kenji Hattori, Shigeru Okamoto, Toru Sawada, Avraham Raz and Takeshi Kubo

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2475::AID-CNCR25>3.0.CO;2-1

      • original image
      • original image
      • original image
      • original image

      Thyroid carcinomas of follicular cell origin consistently express galectin-3, whereas neither benign thyroid adenomas nor normal thyroid tissues show detectable amounts of galectin-3. Immunoblotting analysis of galectin-3 in fine-needle aspirates assists in making a presurgical differential diagnosis between benign and malignant thyroid neoplasms.

    25. You have free access to this content
      The role of high resolution pulsed and color Doppler ultrasound in the differential diagnosis of benign and malignant lymphadenopathy : Results of multivariate analysis (pages 2485–2490)

      Francesco Dragoni, Claudio Cartoni, Edoardo Pescarmona, Flavia Chiarotti, Maria Puopolo, Enrico Orsi, Patrizia Pignoloni, Cinzia De Gregoris and Franco Mandelli

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2485::AID-CNCR26>3.0.CO;2-Y

      • original image
      • original image

      High resolution pulsed and color Doppler ultrasound provides information that is useful in making correct differential diagnoses of malignant and benign lymphadenopathy.

  3. Correspondence

    1. Top of page
    2. Editorial
    3. Original Articles
    4. Correspondence
    1. Anatomic Site

      You have free access to this content
      Desmoplastic and desmoplastic neurotropic melanoma : Experience with 280 patients (pages 2491–2492)

      Igor Shendrik and David N. Silvers

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2491::AID-CNCR27>3.0.CO;2-5

    2. You have free access to this content
      Author reply (page 2492)

      Michael J. Quinn, Kerry A. Crotty and John F. Thompson

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2492::AID-CNCR28>3.0.CO;2-#

    3. You have free access to this content
      Outcome and complications of epidural analgesia in patients with chronic cancer pain (page 2493)

      Sebastiano Mercadante

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2493::AID-CNCR29>3.0.CO;2-U

    4. You have free access to this content
      Author reply (page 2494)

      Peter Sillevis Smitt, Anna Tsafka and Charles Vecht

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2494::AID-CNCR30>3.0.CO;2-G

    5. You have free access to this content
      Prenatal exposure to metronidazole and risk of childhood cancer : A retrospective cohort study of children younger than 5 years (page 2495)

      Octavio Berbel-Tornero, Juan A. López-Andreu and Josep Ferris-Tortajada

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2495::AID-CNCR31>3.0.CO;2-A

    6. You have free access to this content
      Author reply (pages 2496–2495)

      Wayne A. Ray

      Version of Record online: 19 NOV 2000 | DOI: 10.1002/(SICI)1097-0142(19990601)85:11<2496::AID-CNCR32>3.0.CO;2-4

SEARCH

SEARCH BY CITATION